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Summary
Background Social anxiety disorder—a chronic and naturally unremitting disease that causes substantial impairment—
can be treated with pharmacological, psychological, and self-help interventions. We aimed to compare these 
interventions and to identify which are most eﬀ ective for the acute treatment of social anxiety disorder in adults.
Methods We did a systematic review and network meta-analysis of interventions for adults with social anxiety 
disorder, identified from published and unpublished sources between 1988 and Sept 13, 2013. We analysed 
interventions by class and individually. Outcomes were validated measures of social anxiety, reported as 
standardised mean differences (SMDs) compared with a waitlist reference. This study is registered with 
PROSPERO, number CRD42012003146.
Findings We included 101 trials (13 164 participants) of 41 interventions or control conditions (17 classes) in the 
analyses. Classes of pharmacological interventions that had greater eﬀ ects on outcomes compared with waitlist 
were monoamine oxidase inhibitors (SMD –1·01, 95% credible interval [CrI] –1·56 to –0·45), benzodiazepines 
(–0·96, –1·56 to –0·36), selective serotonin-reuptake inhibitors and serotonin–norepinephrine reuptake inhibitors 
(SSRIs and SNRIs; –0·91, –1·23 to –0·60), and anticonvulsants (–0·81, –1·36 to –0·28). Compared with waitlist, 
eﬃ  cacious classes of psychological interventions were individual cognitive–behavioural therapy (CBT; SMD –1·19, 
95% CrI –1·56 to –0·81), group CBT (–0·92, –1·33 to –0·51), exposure and social skills (–0·86, –1·42 to –0·29), 
self-help with support (–0·86, –1·36 to –0·36), self-help without support (–0·75, –1·25 to –0·26), and psychodynamic 
psychotherapy (–0·62, –0·93 to –0·31). Individual CBT compared with psychological placebo (SMD –0·56, 95% CrI 
–1·00 to –0·11), and SSRIs and SNRIs compared with pill placebo (–0·44, –0·67 to –0·22) were the only classes of 
interventions that had greater eﬀ ects on outcomes than appropriate placebo. Individual CBT also had a greater 
eﬀ ect than psychodynamic psychotherapy (SMD –0·56, 95% CrI –1·03 to –0·11) and interpersonal psychotherapy, 
mindfulness, and supportive therapy (–0·82, –1·41 to –0·24).  
Interpretation Individual CBT (which other studies have shown to have a lower risk of side-eﬀ ects than 
pharmacotherapy) is associated with large eﬀ ect sizes. Thus, it should be regarded as the best intervention for the 
initial treatment of social anxiety disorder. For individuals who decline psychological intervention, SSRIs show the 
most consistent evidence of beneﬁ t.
Funding National Institute for Health and Care Excellence.
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Introduction
Social anxiety disorder, or social phobia, aﬀ ects 7% of the 
population1 and follows a chronic and debilitating course 
if untreated.2 Findings from meta-analyses suggest 
that the disorder responds well to pharmacological,3 
psychological,4 and self-help interventions,5 but most 
reviews have been limited to pairwise comparisons of 
subsets of these interventions.
Network meta-analysis has the advantage that all 
interventions that have been tested in randomised 
controlled trials (RCTs) can be simultaneously compared 
and their eﬀ ects can be estimated relative to each other 
and to a common reference condition (eg, waitlist). 
Estimates of the eﬀ ects of pairs of treatments that have 
often, rarely, or never been directly compared in a RCT 
can be calculated. As a consequence, network meta-
analysis overcomes some of the limitations of traditional 
meta-analysis, in which conclusions are largely restricted 
to comparisons between treatments that have been 
directly compared in RCTs.
We undertook a network meta-analysis of all 
psychological and pharmacological interventions that 
are used in routine clinical practice for the initial 
treatment of social anxiety disorder and have been 
tested in RCTs.
Methods
Search strategy and selection criteria
We did a systematic review of interventions for social 
anxiety disorder according to Preferred Reporting Items 
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for Systematic reviews and Meta-Analyses (PRISMA) 
guidelines.6 We searched the following databases between 
1988 and Sept 13, 2013, with no language limits set, for 
published and unpublished studies on treatment of adults 
with social anxiety disorder: Australian Education Index, 
Allied and Complementary Medicine Database, Applied 
Social Services Index and Abstracts, British Education 
Index, Cochrane Database of Systematic Reviews, 
CENTRAL, Cumulative Index to Nursing and Allied Health 
Literature, Database of Abstracts of Reviews and 
Eﬀ ectiveness, Embase, Education Resources in Curriculum, 
Health Management Information Consortium, Health 
Technology Assessment, International Bibliography of 
Social Science, Medline, PreMEDLINE, PsycBOOKS, 
PsycEXTRA, PsycINFO, Sociological Abstracts, Social 
Services Abstracts, and Social Sciencies Citation Index 
(appendix A). We also searched trial registries and reference 
lists of reviews and included studies. We consulted a group 
of experts from the National Institute for Health and Care 
Excellence (NICE) Guideline Development Group to 
identify relevant studies. We also wrote to authors of 
included studies to request trial registration details and 
unpublished outcomes and data; we also asked them to 
identify other potentially relevant studies.
All citations were screened by one author (KK or 
EM-W) who excluded citations that were not related to 
trials or to social anxiety disorder; potentially relevant 
citations were checked independently by a second author 
(EM-W or KK). Study characteristics, outcomes, and risk 
of bias7 were extracted by one author (KK or EM-W) and 
checked independently by a second (EM-W or KK).
Randomised clinical trials of interventions for adults 
aged at least 18 years who fulﬁ lled diagnostic criteria for 
social anxiety disorder were included. Studies that 
primarily focused on the treatment of comorbid disorders 
(eg, substance abuse) were excluded, but participants in 
the included studies often met criteria for another 
disorder (eg, depression) and were included. Eligible 
interventions were oral drugs (ﬁ xed or ﬂ exible doses), 
psychological or behavioural interventions (eg, promotion 
of exercise; panel), and combinations of interventions. 
Pharmacological interventions did not need to be 
licensed for social anxiety disorder, but interventions not 
used routinely in the treatment of social anxiety disorder, 
according to the consensus of the investigators and the 
NICE Guideline Development Group for the guideline 
Social anxiety disorder: recognition, assessment and 
treatment, were excluded (ie, exposure with a cognitive 
enhancer, surgical interventions, injected drugs, and 
antipsychotics). Studies of computerised cognitive bias 
modiﬁ cation were analysed in a separate review 
(unpublished). We excluded drugs that are no longer 
marketed (eg, brofaromine) if trials compared them only 
with placebo because these trials would not provide 
information about eligible interventions.
We limited the network meta-analysis to interventions 
that people with social anxiety disorder and clinicians 
might regard as ﬁ rst-line treatments because network 
analysis assumes that treatment eﬀ ects are transferable 
across studies. Ideally, all trial populations included in the 
network meta-analysis could have been eligible for all the 
treatment options investigated. Clinically, people choosing 
a ﬁ rst-line intervention have a diﬀ erent set of treatment 
options compared with people choosing second-line 
interventions; there would be a high risk that the 
assumption of exchangeability would be violated by the 
inclusion of clinically heterogeneous populations 
(eg, people who had not responded to treatments assessed 
in other studies). We identiﬁ ed eligible interventions by 
reviewing published and unpublished studies and through 
consultation with clinicians and experts (including people 
with social anxiety disorder, pharmacists, psychologists, 
and psychiatrists). We included interventions rather than 
Panel: Deﬁ nition of psychological interventions
Promotion of exercise
Behavioural change programmes that promote increased physical activity.
Exposure and social skills
Behavioural interventions that involve systematic exposure to social interactions or public 
speaking, but that do not include explicit cognitive techniques.
Group CBT
Therapist-led, group-based interventions that use both behavioural strategies 
(eg, exposure) and various cognitive strategies (eg, cognitive restructuring, video 
feedback, and attention training). Speciﬁ c CBT manuals were followed for this 
intervention or the study investigators described the intervention as CBT.
Individual CBT
Individual interventions for which speciﬁ c CBT manuals were followed or that were 
described as CBT by study investigators.
Other psychological therapy
Psychological therapies not included elsewhere were grouped to improve estimates of 
variance for the class model. This class includes the speciﬁ c eﬀ ects of interpersonal 
psychotherapy, mindfulness training, and supportive therapy.
Psychodynamic psychotherapy
Short-term psychodynamic psychotherapy, for which a treatment manual speciﬁ cally for 
social anxiety disorder can be followed.
Psychological placebo
A psychological intervention that includes features common to most well-undertaken 
psychological therapies (ie, non-speciﬁ c components of treatment) and that was 
designed as a credible intervention.
Self-help with support
Interventions (usually CBT based) that are delivered by book or computer with limited 
therapist support (eg, short meetings, email support, or phone calls). For the purpose of clinical 
trials, participants typically received clinical interviews at the beginning and end of treatment.
Self-help without support
Interventions (usually CBT based) that are delivered exclusively by book or computer. 
For the purpose of clinical trials, participants were interviewed at the beginning and end 
of treatment.
CBT=cognitive–behavioural therapy.
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excluded them if some experts thought they could be used 
as a ﬁ rst-line treatment.
Statistical analysis
If a study reported continuous results for participants who 
completed the study only, as well as continuous results 
that accounted for missing data (eg, eﬀ ects calculated 
using multiple imputation), we extracted the data that 
accounted for missing data. Studies reported several 
measures of social anxiety, none of which were common to 
all trials, so we calculated treatment eﬀ ects for each study 
as a standardised mean diﬀ erence (SMD). To reduce 
measurement error, we calculated the mean eﬀ ect 
(Hedges’ g) of all eligible scales for studies that reported 
more than one measure, taking between-scale correlation 
into account.8 For trials that reported only the change 
from baseline, the SD at baseline was used to ensure 
standardising constants were comparable across trials. 
Based on published psychometric properties and data 
from clinically referred participants who completed several 
measures (appendix A), we assumed that measures were 
equally responsive and had a mean correlation of 0·65.
Where reported, we also extracted data for recovery 
from social anxiety disorder (ie, no longer meeting 
criteria for the diagnosis) assuming that study dropouts 
had not recovered. We used the relation between 
continuous outcomes and recovery to estimate the 
treatment eﬀ ect for all studies, including those that did 
not report recovery (appendix A).
We did a Bayesian random-eﬀ ects network meta-
analysis,9 which accounts for the correlation between 
trial-speciﬁ c eﬀ ects and random eﬀ ects of trials with 
more than two arms.10 We analysed interventions by 
class (eg, selective serotonin-reuptake inhibitors and 
serotonin-norepinephrine reuptake inhibitors [SSRIs 
and SNRIs]) and individually (eg, sertraline). In general, 
treatments with similar mechanisms of action were 
grouped in classes in which pooled eﬀ ects were assumed 
to be similar. This grouping had the eﬀ ect of drawing 
individual treatment eﬀ ects towards the class mean. We 
used non-informative priors, except for the prior for 
within-class variability. Because there were few data to 
reliably estimate within-class variation, this prior was 
informative and was restricted with an inverse-gamma 
prior. This restriction limited variability to a clinically 
plausible range and had the eﬀ ect of restricting the 
eﬀ ect of outliers within a class; speciﬁ c interventions 
with inconsistent results based on limited data would 
have otherwise had an undue eﬀ ect on the results. For 
treatments not belonging to a class, we assumed no 
class variability and estimated only between-study 
heterogeneity. Combination interventions were included 
in a class because analysing of each combination as a 
distinct class would underestimate true variance 
(appendix A).
We estimated the eﬀ ect for each class and for each 
individual intervention using Markov chain Monte 
Carlo implemented in WinBUGS version 1.4.3.11 The 
ﬁ rst 20 000 iterations were discarded, and 50 000 further 
iterations were run. Two chains with diﬀ erent initial 
values were run simultaneously to assess convergence 
using the Gelman–Rubin diagnostic trace plots. We 
estimated eﬀ ects with and without the consistency 
assumptions for individual treatment eﬀ ects (ie, without 
grouping by class) and compared the residual deviance 
of each to assess consistency.12 We compared the ﬁ t of 
the standard model to the class model by comparing the 
residual deviance, and we chose the model with the 
lowest deviance information criterion.9 We used 
treatment eﬀ ects to estimate change on continuous 
measures and the absolute rate of recovery for each 
intervention with 95% credible intervals (CrIs). Main 
eﬀ ects are reported compared with waitlist, which was 
chosen as the reference treatment a priori.
All outcomes and study eﬀ ects used in the analysis are 
available online (appendix B).
This study is registered with PROSPERO, number 
CRD42012003146.
Role of the funding source
NICE commissioned the National Collaborating Centre 
for Mental Health (NCCMH) to develop guidance for 
10 894 studies identiﬁed
10 893 through database searching
1 through other sources
7592 studies screened
156 full-text studies assessed for
eligibility
101 studies included in qualitative
synthesis and quantitative synthesis
meta-analysis
3302 duplicates removed
7436 excluded
7424 not relevant
4 ongoing
8 could not locate full report
55 excluded
29 not an eligible intervention
20 no usable data
2 not connected to the network
2 implausible outcomes
1 diﬀerent population
1 not a randomised trial
Figure 1: PRISMA ﬂ owchart
PRISMA=Preferred Reporting Items for Systematic reviews and Meta-Analyses. 
See Online for appendix B
See Online for appendix A
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the identiﬁ cation and management of social anxiety 
disorder. NICE also approved funding for the Technical 
Support Unit to support NCCMH in undertaking a 
network meta-analysis of intervention studies. 
The funder of the study had no further role in study 
design, data collection, data analysis, data interpretation, 
or writing of the report. All authors had full access to all 
the data in the study and had ﬁ nal responsibility for the 
decision to submit for publication. 
Results
Between 1988 and Sept 13, 2013, we identiﬁ ed 
168 potentially eligible studies, 12 of which were 
excluded: four were ongoing studies and for eight 
studies we could not identify a complete study report. 
We assessed 156 studies for eligibility (ﬁ gure 1). 
55 studies were excluded (appendix A) because they did 
not include an eligible intervention (n=29), reported no 
usable data (n=20), included no intervention already in 
the analysis and thus were not connected to this 
network (n=2),  reported implausible outcomes (n=2), 
included a diﬀ erent population (n=1), or were not a 
randomised trial (n=1). 101 studies were included in the 
network analysis (appendix A).
14 229 participants were randomly assigned in the trials, 
and 13 164 were included in the analysis because some trials 
did not report outcomes for all participants. There 
were 18–839 participants per study. Trials assessed 
41 interventions or control conditions, which were grouped 
into 17 classes. Most trials included two groups (n=64), but 
some included three (n=28), four (n=7), or ﬁ ve groups (n=2). 
The median and mean duration of treatment was 12 weeks 
(range 2–28 weeks). Few studies provided controlled results 
for long-term follow-up, and so long-term follow-up data 
were not included in our analyses.
Participants had severe and longstanding social 
anxiety; of 65 studies reporting baseline Liebowitz Social 
Anxiety Scale13 scores, the median of means was 78 
(appendix A). The median of means age was 36 years and 
the median of percentages of participants who were white 
was 80%. About half of the included participants were 
women (52% median of means). Most psychological 
studies did not exclude participants receiving drug 
treatment, but trials of psychological interventions 
generally required participants to be on a stable dose of 
drug treatment for several months before random 
allocation. Participants were not receiving drug treatment 
in 44 trials. In 27 trials, 27% of participants (median of 
means) were receiving drug treatment at randomisation. 
The demographic characteristics of participants were 
similar across comparisons (appendix A), and there were 
no obvious diﬀ erences in the initial severity of social 
anxiety symptoms; variation in severity was limited 
because studies had similar inclusion criteria.
We assessed all included trials for risk of bias 
(appendix A). Sequence generation and allocation 
concealment were adequately described in 74 and 
69 trials, respectively (appendix A). Trials of psychological 
interventions were regarded as at high risk of bias for 
participant and provider masking per se, although 
treatment eﬀ ects and side-eﬀ ects could also make 
maintenance of masking diﬃ  cult in pharmacological 
trials. Most reported outcomes were self-rated, and 
assessors were aware of treatment assignment in ﬁ ve 
trials. For incomplete outcome data, 26 trials were at high 
risk of bias (eg, those that reported only completer 
analyses and those with lots of missing data), and how 
missing data were handled was unclear in four trials.
Most included trials were not registered; only 37 trials 
were at low risk of selective outcome reporting bias 
(appendix A). In addition to risk of selective outcome 
reporting for included studies, there is risk of reporting 
bias because we could not locate a full report for eight 
studies, 20 studies reported no usable data, and two 
studies reported implausible outcomes. Results can be 
overestimated as a result of publication bias, particularly 
for interventions developed before mandatory trial 
registration. Unpublished information was obtained 
from trial investigators for 34 studies, including 
unpublished outcomes for 22 trials.
Excluding masking of participants and providers, 
which was impossible in studies of psychological 
interventions and diﬃ  cult to maintain in studies of 
pharmacological interventions, only 28 trials were at 
low risk of bias for all other domains assessed by the 
Cochrane risk of bias assessment (appendix A).
Figure 2 shows the network of comparisons 
among classes. Of 820 possible comparisons among 
Figure 2: Network diagram representing direct comparisons among classes
The width of lines represents the number of trials in which each direct comparison is made. The size of each circle 
represents the number of people who received each treatment. CBT=cognitive–behavioural therapy. SNRI=serotonin–
norepinephrine reuptake inhibitor. SSRI=selective serotonin-reuptake inhibitor. 
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41 intervention or control conditions, 84 were studied 
directly (appendix A). 76 studies compared interventions 
with a control group; most drugs were compared with 
placebo, and most psychological interventions were 
compared with waitlist or with psychological placebo. 
The network also included 58 studies that compared active 
interventions, including four studies that compared 
psychological with pharmacological interventions.
25 trials also reported recovery (appendix A), and we 
compared eﬀ ects for continuous measures and loss of 
diagnosis for these studies, which suggested that 
continuous values provide lower treatment eﬀ ects 
compared with odds ratios of recovery.
There was potential for inconsistency in nine of the 
44 loops in the network—others were formed by multi-
arm trials that are consistent by deﬁ nition. There were 
no substantial diﬀ erences in magnitude and direction 
between the results of the network meta-analysis and the 
results of pairwise comparisons. The posterior mean of 
the residual deviance was 165·3 in the standard network 
meta-analysis model compared with 176·3 in the 
independent-eﬀ ect model that compares favourably with 
the number of treatment groups (n=148), suggesting the 
network better estimates treatment eﬀ ects than pairwise 
analyses alone with no evidence of inconsistency.9
The random-eﬀ ects class model was a good ﬁ t to 
the data compared with the individual-eﬀ ects model 
(deviance information criterion 364·8 vs 371·0; lower 
values suggest a better ﬁ t), although the between-trials 
SD for heterogeneity had a posterior median of 
0·19 (95% CrI 0·14–0·25). That is, there was some 
variability between classes that might be attributable to 
diﬀ erences among the individual treatments beyond the 
within-class variability. For classes with few members, 
there was little information about within-class variability 
and the prior for within-class variability led to increased 
uncertainty in the estimated class eﬀ ects.
All pharmacological interventions apart from nor-
adrenergic and speciﬁ c serotonergic antidepressants had 
greater eﬀ ects on outcomes compared with waitlist (table; 
ﬁ gure 3). Mirtazapine, a noradrenergic and sepciﬁ c 
serotonergic antidepressant, was the only pharmacological 
intervention in a class by itself; its eﬀ ect was not greater 
than that for waitlist (class eﬀ ect SMD –0·80, 95% CrI 
–1·64 to 0·01), but only 30 people received the intervention. 
The largest eﬀ ects were for MAOIs (class eﬀ ect 
SMD –1·01, 95% CrI –1·56 to –0·45) and benzodiazepines 
(–0·96, –1·56 to –0·36), but the evidence for these eﬀ ects 
was limited compared with evidence for SSRIs and SNRIs 
(–0·91, –1·23 to –0·60); more people received SSRIs and 
SNRIs (n=4043) than all other pharmacological 
interventions (n=999) or all psychological interventions 
(n=3312).
All psychological interventions apart from promotion 
of exercise and other psychological therapies (supportive 
therapy, mindfulness, and interpersonal psychotherapy) 
had greater eﬀ ects on outcomes than did waitlist (table; 
Trials Participants Class eﬀ ect SMD (95% CrI) Individual eﬀ ect SMD 
(95% CrI)
Controls
Waitlist 28 802 Reference Reference
Placebo pill 42 3623 –0·47 (–0·71 to –0·23) ··
Psychological placebo 6 145 –0·63 (–0·90 to –0·36) ··
Pharmacological interventions
Anticonvulsants 5 242 –0·81 (–1·36 to –0·28) ··
Gabapentin 1 34 ·· –0·89 (–1·42 to –0·37)
Levetiracetam 1 9 ·· –0·83 (–1·50 to –0·18)
Pregabalin 3 199 ·· –0·72 (–1·07 to –0·37)
Benzodiazepines 5 112 –0·96 (–1·56 to –0·36) ··
Alprazolam 1 12 ·· –0·85 (–1·40 to –0·30)
Clonazepam 4 100 ·· –1·07 (–1·44 to –0·70)
Monoamine oxidase 
inhibitors
11 615 –1·01 (–1·56 to –0·45) ··
Moclobemide 6 490 ·· –0·74 (–1·03 to –0·44)
Phenelzine 5 125 ·· –1·28 (–1·57 to –0·98)
Noradrenergic and speciﬁ c 
serotonergic antidepressants 
(mirtazapine)
1 30 –0·80 (–1·64 to 0·01) –0·81 (–1·45 to –0·16)
SSRIs and SNRIs 32 4043 –0·91 (–1·23 to –0·60) ··
Citalopram 2 18 ·· –0·83 (–1·28 to –0·39)
Escitalopram 2 675 ·· –0·88 (–1·20 to –0·56)
Fluoxetine 3 107 ·· –0·87 (–1·16 to –0·57)
Fluvoxamine 5 500 ·· –0·94 (–1·25 to –0·63)
Paroxetine 12 1449 ·· –0·99 (–1·26 to –0·73)
Sertraline 3 535 ·· –0·92 (–1·23 to –0·61)
Venlafaxine 5 759 ·· –0·96 (–1·25 to –0·67)
Psychological and behavioural interventions
Exercise promotion 1 18 –0·36 (–1·32 to 0·61) –0·36 (–1·07 to 0·36)
Exposure and social skills 10 227 –0·86 (–1·42 to –0·29) ··
Exposure in vivo 9 199 ·· –0·83 (–1·07 to –0·59)
Social skills training 1 28 ·· –0·88 (–1·38 to –0·38)
Group CBT 28 984 –0·92 (–1·33 to –0·51) ··
Heimberg model 11 338 ·· –0·80 (–1·02 to –0·58)
Other (no model speciﬁ ed) 16 583 ·· –0·85 (–1·04 to –0·68)
Enhanced CBT 1 63 ·· –1·10 (–1·49 to –0·71)
Individual CBT 15 562 –1·19 (–1·56 to –0·81) ··
Hope, Heimberg, and 
Turk model
2 53 ·· –1·02 (–1·42 to –0·62)
Other (no model speciﬁ ed) 6 163 ·· –1·19 (–1·48 to –0·89)
Clark and Wells cognitive 
therapy model
3 97 ·· –1·56 (–1·85 to –1·27)
Clark and Wells cognitive 
therapy shortened sessions
4 249 ·· –0·97 (–1·21 to –0·74)
Other psychological therapy 7 182 –0·36 (–0·84 to 0·12) ··
Interpersonal 
psychotherapy
2 64 ·· –0·43 (–0·83 to 0·04)
Mindfulness training 3 64 ·· –0·39 (–0·82 to 0·03)
Supportive therapy 2 54 ·· –0·26 (–0·72 to 0·20)
Psychodynamic 
psychotherapy
3 185 –0·62 (–0·93 to –0·31) ··
Self-help with support 16 748 –0·86 (–1·36 to –0·36) ··
Book with support 3 52 ·· –0·85 (–1·17 to –0·53)
Internet with support 13 696 ·· –0·88 (–1·04 to –0·71)
(Table continues on next page)
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ﬁ gure 3). In decreasing order of eﬀ ect size, these were 
individual cognitive–behavioural therapy (CBT; class 
eﬀ ect SMD –1·19, 95% CrI –1·56 to  –0·81), group CBT 
(–0·92, –1·33 to –0·51), exposure and social skills (–0·86, 
–1·42 to –0·29), self-help with support (–0·86, 
–1·36 to –0·36), self-help without support (–0·75, 
–1·25 to –0·26), and psychodynamic psychotherapy 
(–0·62, –0·93 to –0·31).
Compared with pill placebo, MAOIs (SMD –0·53, 
95% CrI –1·06 to –0·01) and SSRIs and SNRIs (–0·44, 
–0·67 to –0·22) had greater eﬀ ects on outcomes, and 
pill placebo itself had a greater eﬀ ect than waitlist 
(–0·47, –0·71 to –0·23; ﬁ gure 4). Of the psychological 
interventions, only individual CBT had a greater eﬀ ect 
on outcomes than psychological placebo (SMD –0·56, 
95% CrI –1·00 to –0·11). Individual CBT also had a 
greater eﬀ ect than pill placebo (SMD –0·72, 95% CrI 
–1·13 to –0·30), psychodynamic psychotherapy 
(–0·56, –1·00 to –0·11), and other therapies (–0·82, 
–1·41 to –0·24; ﬁ gure 4). Figure 4 also expresses these 
treatment eﬀ ects on the probability of recovery (ie, no 
longer meeting criteria for diagnosis).
Of the pharmacological interventions, there were 
greater individual eﬀ ects compared with waitlist for all 
SSRIs (citalopram, escitalopram, ﬂ uoxetine, ﬂ uvoxamine, 
paroxetine, and sertraline) and the SNRI venlafaxine. 
Eﬀ ects of SSRIs and SNRIs were measured in 32 studies, 
and they were similar in magnitude within the class 
except for citalopram, which was assessed in two small 
studies; all individual SMDs were within 0·08 of the class 
SMD. Compared with waitlist, the eﬀ ects of the MOAIs 
phenelzine (SMD –1·28, –1·57 to –0·98) and moclobemide 
(–0·74, –1·03 to –0·44) were also greater; however, only 
125 people received phenelzine across ﬁ ve trials and the 
results might be overestimated. The large eﬀ ect for 
phenelzine was dissimilar to the small eﬀ ect for 
moclobemide (appendix B), which was the only other 
MAOI included in the analysis.
The most eﬃ  cacious psychological interventions were 
individual CBT—following the Clark and Wells model 
(SMD –1·56, 95% CrI –1·85 to –1·27),14 the Hope, Heimberg 
and Turk model (–1·02, –1·42 to –0·62),15 and CBT not 
following a named manual (–1·19, –1·48 to –0·89)—and 
group enhanced CBT (–1·10,  –1·49 to –0·71; table). 
Supported self-help was eﬃ  cacious when provided via the 
internet (SMD –0·88, 95% CrI –1·04 to –0·71) or by book 
(–0·85, –1·17 to –0·53). Psychological placebo also had a 
greater eﬀ ect than waitlist (SMD –0·63, 95% CrI 
–0·90 to –0·36), and its eﬀ ect was comparable to 
psychodynamic psychotherapy (–0·62, –0·93 to –0·31).
Several drugs had greater eﬀ ects on outcomes 
compared with pill placebo: clonazepam, escitalopram, 
ﬂ uoxetine, ﬂ uvoxamine, moclobemide, paroxetine, 
phenelzine, sertraline, and venlafaxine (appendix B). 
Citalopram was the only included SSRI that did not 
have a greater eﬀ ect than placebo. Of the psychological 
interventions, only Clark and Wells cognitive therapy 
model, Clark and Wells cognitive therapy model with 
shortened sessions, individual CBT, and group 
enhanced CBT had greater eﬀ ects than psychological 
placebo. There was no consistent evidence of diﬀ erential 
eﬃ  cacy within pharmacotherapies. There was some 
evidence of diﬀ erential eﬃ  cacy within the psychological 
interventions. Individual CBT according to the Clark 
and Wells manual showed the most consistent evidence 
of greater eﬀ ects, as suggested by non-overlapping 
95% CrIs between this intervention and most other 
psychological intervention (table).
Combined interventions had greater eﬀ ects on 
outcomes than waitlist overall (SMD –1·30, 95% CrI 
Figure 3: Eﬀ ect of each class of intervention compared with waitlist
Data are standardised mean diﬀ erence and 95% credible intervals compared with waitlist as a reference. 
CBT=cognitive–behavioural therapy. SNRI=serotonin–norepinephrine reuptake inhibitor. SSRI=selective serotonin-
reuptake inhibitor.
 
 
Waitlist (reference)
Placebo pill
Psychological placebo
Promotion of exercise
Self-help without support
Self-help with support
Anticonvulsants
Noradrenergic and speciﬁc
serotonergic antidepressants
SSRIs and SNRIs
Benzodiazepines
Monoamine oxidase inhibitors
Exposure and social skills
Other psychological therapy
Psychodynamic psychotherapy
Group CBT
Individual CBT
Combined CBT
–2·0 –1·5 –0·5 0 0·5–1·0
Standardised mean diﬀerence
Trials Participants Class eﬀ ect SMD (95% CrI) Individual eﬀ ect SMD 
(95% CrI)
(Continued from previous page)
Self-help without support 9 406 –0·75 (–1·25 to –0·26) ··
Book without support 4 136 ·· –0·84 (–1·08 to –0·60)
Internet without support 5 270 ·· –0·66 (–0·94 to –0·39)
Combined interventions
Combined 5 156 –1·30 (–1·73 to –0·88) ··
Group CBT and 
moclobemide
1 22 ·· –1·23 (–1·72 to –0·74)
Group CBT and ﬂ uoxetine 1 59 ·· –0·95 (–1·34 to –0·58)
Group CBT and phenelzine 1 32 ·· –1·69 (–2·10 to –1·27)
Psychodynamic and 
clonazepam
1 29 ·· –1·28 (–1·82 to –0·74)
Paroxetine and clonazepam 1 14 ·· –1·35 (–1·93 to –0·79)
CBT=cognitive–behavioural therapy. CrI=credible interval. SMD=standardised mean diﬀ erence. SNRI=serotonin–
norepinephrine reuptake inhibitor. SSRI=selective serotonin-reuptake inhibitor.
Table: Summary of treatment eﬀ ects compared with waitlist 
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–1·73 to –0·88; table; ﬁ gure 4), but the quality of the 
evidence was poor. Five diﬀ erent combinations of 
psychological and pharmacological interventions were 
assessed in one trial each; all reported large eﬀ ects, but 
only 156 participants received combined interventions 
across all ﬁ ve trials. There was no evidence that 
combined interventions had greater eﬀ ects than the 
leading monotherapies (table). 
Discussion
To our knowledge, this is the ﬁ rst time that psycho-
logical and pharmacological interventions for a mental 
health problem have been compared in network meta-
analysis.16 The ﬁ ndings conﬁ rm that social anxiety 
disorder responds well to treatment, although many 
people continue to experience some symptoms after 
the end of the acute treatment phase.
Several classes of pharmacological and psychological 
intervention had greater eﬀ ects on outcomes than did 
waitlist. Individual CBT and the class including SSRIs and 
SNRIs also had greater eﬀ ects on outcomes than 
appropriate placebos, suggesting that they have speciﬁ c 
eﬀ ects. Psychological and pill placebo had greater eﬀ ects 
than waitlist; investigation of these eﬀ ects suggests that 
non-speciﬁ c factors might account for about half the total 
eﬀ ects of individual CBT and SSRIs. Comparisons between 
psychological interventions revealed some evidence of 
diﬀ erential eﬀ ects. In particular, individual CBT had a 
greater eﬀ ect than psychodynamic psychotherapy and 
other psychological therapies (interpersonal psychotherapy, 
mindfulness, and supportive therapy). Many of the 
psychological treatments with large eﬀ ects were versions of 
CBT (individual, group, or self-help), suggesting that CBT 
might be eﬃ  cacious in a range of formats. Psychodynamic 
psychotherapy was also eﬀ ective, although its eﬀ ects were 
similar to psychological placebo.
Because pharmacological and psychological inter-
ventions were both eﬃ  cacious, a logical question to ask 
is whether combined interventions might be more 
helpful than either intervention alone. Although large 
eﬀ ect sizes were noted with combined treatments, only 
a few small studies were included, and there was no 
evidence that any combination was more eﬃ  cacious 
than the leading pharmacological or psychological 
monotherapy in that combination.
There was little evidence of diﬀ erential eﬃ  cacy 
within or between classes of drugs. In the case of 
SSRIs and SNRIs, this ﬁ nding is consistent with data 
from a previous network analysis, which showed no 
diﬀ erences in eﬃ  cacy but diﬀ erences in tolerability.17 
Figure 4: Eﬃ  cacy of classes of interventions
Classes of interventions are ordered according to eﬃ  cacy ranking from largest mean eﬀ ect (top, left) to smallest mean eﬀ ect (bottom, right). Data in blue represent the eﬀ ects on symptoms of 
social anxiety (SMD [95% CrI]); SMD less than 0 favours the intervention in the row. Data in green represent the eﬀ ects on recovery (RR [95% CrI]); RR greater than 1 favours the intervention in 
the column. Signiﬁ cant results are shaded dark blue and dark green. CBT=cognitive–behavioural therapy. CrI=credible interval. EXER=promotion of exercise. EXPO=exposure and social skills. 
MAOI=monoamine oxidase inhibitors. NSSA=noradrenergic and speciﬁ c serotonergic antidepressants. OTHER=other psychological therapy. PDPT=psychodynamic psychotherapy. 
PSYP=psychological placebo. RR=risk ratio. SHNS=self-help without support. SHWS=self-help with support. SMD=standardised mean diﬀ erence. SNRI=serotonin–norepinephrine reuptake 
inhibitors. SSRI=selective serotonin-reuptake inhibitor.  
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Data for cost-eﬀ ectiveness and side-eﬀ ects both aﬀ ect 
choices, and a cost-eﬀ ectiveness analysis will be reported 
elsewhere. Taking these factors into account, NICE 
recently concluded that individual CBT should be 
oﬀ ered as the treatment of choice for social anxiety 
disorder. For individuals who decline individual CBT, a 
SSRI is recommended for people who would prefer 
drug treatment and CBT-based supported self-help is 
recommended for people who prefer another psycho-
logical intervention. Psychodynamic psycho therapy is 
recommended as a third-line option, and other drugs 
are recommended only for people who do not respond to 
initial treatments.25,30 Thus, NICE recommendations are 
consistent with the results of this study, which suggests 
that increased access to treatment would reduce 
disability and improve quality of life for people with 
social anxiety disorder. 
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In the absence of convincing evidence for diﬀ erential 
eﬃ  cacy, diﬀ erences in tolerability and side-eﬀ ects are 
particularly important in the choice of treatment. 
SSRIs and SNRIs with a short half-life (eg, paroxetine 
and venlafaxine) are associated with the greatest risk 
of discontinuation eﬀ ects, including eﬀ ects during the 
treatment period and after the end of treatment.18,19 
Some side-eﬀ ects such as increased agitation18 and 
sexual dysfunction20 can be especially distressing for 
people with social anxiety disorder, particularly if 
these eﬀ ects are unexpected or if they reinforce 
existing worries. These issues should be discussed 
with patients before starting drug treatment.
We were not able to investigate whether immediate 
treatment eﬀ ects persist or diminish in the long term 
because most trials stopped at the end of treatment. 
Findings from studies that have addressed this issue21,22 
suggest that most people who respond to a SSRI will relapse 
within a few months if the drug is discontinued after acute 
treatment, and about 25% of people who respond to SSRI 
treatment and continue drug treatment will relapse within 
6 months. By contrast, the eﬀ ects of psychological 
interventions are generally well maintained at follow-up,23 
and participants can continue to apply new skills and make 
further gains after the end of acute treatment.24 For this 
reason, and because of the lower risk of side-eﬀ ects, 
psychological interventions should be preferred over 
pharmacological interventions for initial treatment.25
This study has several limitations. There were only a few 
studies of moderate size for several included interventions, 
and some have only been tested by one or two research 
groups. We included a broad range of interventions, which 
varied in duration, and there might be unknown 
diﬀ erences among participants in diﬀ erent trials. However, 
we did not identify any systematic diﬀ erences in participant 
demographics or initial symptom severity. Direct and 
indirect results were consistent, which provides further 
support to the pooled results. Control conditions were 
heterogeneous and rarely described in detail. Future trials 
should more clearly describe what was intended and what 
was actually received by people in control conditions.26,27 
Statistical power might have been limited because we used 
scores after treatment rather than the change in scores and 
because we calculated eﬀ ects conservatively, estimating 
eﬀ ects accounting for dropout (eg, using last-observation-
carried-forward) where possible. Conversely, pairwise 
analyses of small studies sometimes overestimate eﬀ ects 
compared with large studies.28,29 Uncertainty in mean 
eﬀ ects (ie, large CrIs) suggests that more research would 
improve our understanding of how these treatments 
compare. Speciﬁ cally, large trials that compare active 
interventions and independent replications would improve 
the precision of these estimates and increase conﬁ dence in 
their external validity. We included only outcomes at the 
end of treatment; trials comparing active interventions 
with controlled long-term follow-up would provide better 
evidence of sustained eﬀ ects.
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